Secukinumab improves cutaneous adipose tissue inflammatory signatures in psoriasis patients.

This randomized placebo-controlled trial investigated the effects of secukinumab on the cutaneous adipose tissue (CAT) transcriptome in patients with psoriasis. The study population consisted of 82 participants, comparing secukinumab treatment against placebo. Primary assessments focused on gene expression profiles and inflammatory pathways within lesional and non-lesional skin-associated adipose tissue.

Analysis of differentially expressed transcripts revealed that psoriatic CAT exhibited 2132 differentially expressed transcripts compared with healthy controls. Obese psoriatic CAT demonstrated a more than 2-fold higher number of differentially expressed genes than non-obese counterparts. Treatment with secukinumab markedly improved inflammatory signatures in psoriatic CAT. Notably, greater improvements in these inflammatory signatures were observed in obese patients relative to non-obese patients.

Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported in the study. Specific p-values or confidence intervals for the primary outcomes were not provided in the available data. The study did not report specific limitations, funding sources, or conflicts of interest. While the results highlight a biological effect of secukinumab on CAT inflammation, the absence of reported safety data and specific statistical measures limits the ability to fully assess clinical risk-benefit profiles. The findings are specific to transcriptomic changes and do not directly translate to standard clinical efficacy metrics like PASI scores.